An executive with more than 20 years of experience in pharmaceutical manufacturing, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. In addition to his work driving growth at Cambridge Therapeutics, Alpine resident John Klein recently launched a new strategic business-consulting firm called Bilogix.
Focused on the growing field of enterprise performance management (EPM), Bilogix uses strategic analysis and consulting to help businesses better compete in an evolving marketplace. With the advent of disruptive technologies such as digital transformation, the Internet of things, mobile applications, and artificial intelligence, many institutions are struggling to keep pace from a technology standpoint.
EPM firms like Bilogix can assist these corporations with making necessary technological shifts and deploying their resources more effectively. With the changing landscape, only businesses that are willing to undergo rigorous examination and strategic transformation will be able to stay competitive as more and more companies focus on innovation.
Focused on the growing field of enterprise performance management (EPM), Bilogix uses strategic analysis and consulting to help businesses better compete in an evolving marketplace. With the advent of disruptive technologies such as digital transformation, the Internet of things, mobile applications, and artificial intelligence, many institutions are struggling to keep pace from a technology standpoint.
EPM firms like Bilogix can assist these corporations with making necessary technological shifts and deploying their resources more effectively. With the changing landscape, only businesses that are willing to undergo rigorous examination and strategic transformation will be able to stay competitive as more and more companies focus on innovation.
